Mutation Spectrum of Hemoglobinopathies in Tunisia
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/6126372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 28.05.2026. Verfasst von Imen Moumni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Cellular Hematology (HMC), Institut Pasteur de Tunis, University of Tunis Elmanar, Tunis, Tunisia, pasteur.tn. Hauptthemen laut MEDLINE: Hemoglobinopathies, Mutation, Hemoglobins, Abnormal. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hemoglobinopathies are the most prevalent recessive disorders worldwide, characterized by wide molecular and clinical heterogeneity. They result from mutations within the alpha‐, beta‐, or delta‐globin gene leading to aberrant expression or protein function. These abnormalities are widely spread throughout the Mediterranean basin. Due to their severity and disabling nature, hemoglobinopathies represent a major public health problem. Mutational screening of abnormal hemoglobins (Hbs) allows the creation of a mutation map, which forms the basis for a potential national prevention program in Tunisia.
Methods
A total of 260 Tunisian subjects were investigated using biochemical and molecular analyses to identify defects in the globin genes (HBA, HBB, and HBD). The study is aimed at determining the molecular spectrum of hemoglobinopathies and contributing to the development of a comprehensive Hb mutation map in Tunisia.
Results
Twenty‐one β ‐thalassemia mutations and 16 rare Hb variants were reported, affecting the HBA, HBD, and HBB genes. Rare Hb variants were identified and described for the first time among Tunisian patients, including Hb A 2 ‐Babinga (HBD:c.410G>A; delta 136: Gly → Asp, GGT → GAT). Other variants, such as Hb Knossos, Hb Summer Hill, Hb Hope, and Hb Köln, which are uncommon in the Mediterranean region, were also detected.
Conclusion
This study provides an updated overview of β ‐thalassemia mutations and rare Hb variants in the Tunisian population. These findings are essential for understanding genetic and clinical diversity, improving the clinical management of hemoglobinopathies, and enhancing public health initiatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Cellular Hematology (HMC), Institut Pasteur de Tunis, University of Tunis Elmanar, Tunis, Tunisia, pasteur.tn.
- Department of Pediatrics: Immunology, Hematology, and Stem Cell Transplantation Bone Marrow Transplant Center, Tunis, Tunisia.
ORCID-Profile: Imen Moumni, Khouloud Khalfaoui, Mariem Chebbi, Leila Chaouch, Houyem Ouragini, Dorra Chaouechi, Fethi Mellouli, Monia Ouederni, Monia Benkhaled, Salem Abbes
Zitieren
APA
Moumni, I., Khalfaoui, K., Chebbi, M., Chaouch, L., Ouragini, H., Chaouechi, D., Mellouli, F., Ouederni, M., Benkhaled, M., Abbes, S., & Menif, S. (2026). Mutation Spectrum of Hemoglobinopathies in Tunisia. Human Mutation, 2026(1). https://doi.org/10.1155/humu/6126372
Vancouver
Moumni I, Khalfaoui K, Chebbi M, Chaouch L, Ouragini H, Chaouechi D, et al. Mutation Spectrum of Hemoglobinopathies in Tunisia. Human Mutation. 2026;2026(1). doi:10.1155/humu/6126372
BibTeX
@article{Moumni2026,
author = {Moumni, Imen and Khalfaoui, Khouloud and Chebbi, Mariem and Chaouch, Leila and Ouragini, Houyem and Chaouechi, Dorra and Mellouli, Fethi and Ouederni, Monia and Benkhaled, Monia and Abbes, Salem and Menif, Samia},
title = {Mutation Spectrum of Hemoglobinopathies in Tunisia},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/6126372}
}
EUVIMED